Edesa Biotech (Nasdaq:EDSA) - Stock Price, News & Analysis

EDSA Stock Overview

A clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. More details

EDSA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 32.7% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($7M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Edesa Biotech, Inc. Competitors

Coeptis Therapeutics Holdings

NasdaqCM:COEP

US$8.0m

Enzon Pharmaceuticals

OTCPK:ENZN

US$5.6m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.0m

Aptevo Therapeutics

NasdaqCM:APVO

US$5.7m

Price History & Performance

Summary of all time highs, changes and price drops for Edesa Biotech
Historical stock prices
Current Share Price	US$2.17
52 Week High	US$6.46
52 Week Low	US$2.05
Beta	0.84
11 Month Change	-36.18%
3 Month Change	-51.56%
1 Year Change	-33.23%
33 Year Change	-95.26%
5 Year Change	-93.80%
Change since IPO	-94.04%

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

Shareholder Returns

	EDSA	US Biotechs	US Market
7D	3.3%	2.5%	2.2%
1Y	-33.2%	16.1%	31.6%

Return vs Industry: EDSA underperformed the US Biotechs industry which returned 16.2% over the past year.

Return vs Market: EDSA underperformed the US Market which returned 31.7% over the past year.

Price Volatility

Is EDSA's price volatile compared to industry and market?
EDSA volatility
EDSA Average Weekly Movement	9.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: EDSA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EDSA's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	16	Par Nijhawan	www.edesabiotech.com

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.

Edesa Biotech, Inc. Fundamentals Summary

How do Edesa Biotech's earnings and revenue compare to its market cap?
EDSA fundamental statistics
Market cap	US$7.05m
Earnings (TTM)	-US$6.93m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Is EDSA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EDSA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$6.93m
Earnings	-US$6.93m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did EDSA perform over the long term?

See historical performance and comparison

EDSA Stock Overview

Risk Analysis

Edesa Biotech, Inc. Competitors

NasdaqCM:COEP

US$8.0m

OTCPK:ENZN

US$5.6m

NasdaqCM:SLRX

US$2.0m

NasdaqCM:APVO

US$5.7m

Price History & Performance

Recent News & Updates

New major risk - Market cap size

Edesa Biotech, Inc. announced that it expects to receive $5.136066 million in funding from Pardeep Nijhawan Medicine Professional Corporation

Edesa Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

Edesa Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech, Inc., Annual General Meeting, May 30, 2024

Recent updates

New major risk - Market cap size

Edesa Biotech, Inc. announced that it expects to receive $5.136066 million in funding from Pardeep Nijhawan Medicine Professional Corporation

Edesa Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

Edesa Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech, Inc., Annual General Meeting, May 30, 2024

Price target decreased by 35% to US$24.00

Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech’S ARDS Drug

Price target decreased by 10% to US$52.33

Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government

New major risk - Market cap size

New minor risk - Share price stability

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023

Edesa Biotech Receives Non-Compliance Notice From Nasdaq

Less than half of directors are independent

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech, Inc. Reports Topline Phase 2B Results for Dermatology Drug

Fda Grants Fast Track to Edesa Biotech's Ards Drug Candidate

No longer forecast to breakeven

Insufficient new directors

Edesa Biotech, Inc. announced that it has received CAD 3.027754 million in funding

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech, Inc. Reports Phase 2b Study Reaches Full Enrollment

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

No longer forecast to breakeven

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Edesa Biotech, Inc. Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Price target decreased to US$16.33

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

High number of new and inexperienced directors

No longer forecast to breakeven

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa Biotech, Inc., Annual General Meeting, May 18, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to Its Board of Directors

Edesa Biotech, Inc. Announces Peter Van Der Velden Resign from Board and Its Committees

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Edesa Biotech, Inc. Announces Positive Phase 2 Data of Monoclonal Antibody in Hospitalized Covid-19 Patients

Edesa Biotech, Inc. Provides Update on Phase 2/3 Clinical Study Evaluating its Monoclonal Antibody Candidate as Single-Dose Therapy for Hospitalized COVID-19 Patients

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech, Inc. Extends Dermatitis Study to Canada

Edesa Biotech, Inc. Completes Independent Data and Safety Monitoring Board Interim Review of COVID-19 Drug Candidate

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Edesa Biotech, Inc. Completes Enrollment of More Than 50% of the Patients Planned for the Phase 2 Portion of Its Ongoing Phase 2/Phase 3 Clinical Study

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

Edesa Biotech, Inc., Annual General Meeting, Apr 22, 2021

Price target raised to US$17.00

Director recently sold US$58k worth of stock

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Earnings beat expectations, revenue disappoints

Edesa Biotech receives C$14M for COVID-19 study